Eskildsen P C, Parving H H, Mogensen C E, Christiansen J S
Acta Med Scand Suppl. 1979;624:79-82. doi: 10.1111/j.0954-6820.1979.tb00724.x.
Creatinine clearance and daily urinary albumin and beta2-microglobulin excretion rates (radio-immunoassays) were measured several times in 14 patients with acromegaly. Eleven patients were treated with bromocriptine, 5 to 55 mg/day. The activity of the disease was assessed by measuring urinary growth hormone excretion (radio-immunoassay). In agreement with previous investigations we found the creatinine clearance elevated. However, no correlation was found between this variable and urinary growth hormone excretion. Urinary albumin and beta 2-microglobulin excretion rates were not significantly different from our previous results in 27 adults control subjects. There was no correlation between urinary growth hormone excretion and urinary albumin or beta 2-microglobulin excretion rates. Bromocriptine treatment reduced urinary growth hormone excretion from 220 to 91 ng/24 hours, p less than 0.01, but no significant alterations were induced in the above mentioned kidney function variables.
对14例肢端肥大症患者多次测量肌酐清除率以及每日尿白蛋白和β2-微球蛋白排泄率（放射免疫测定法）。11例患者接受溴隐亭治疗，剂量为每日5至55毫克。通过测量尿生长激素排泄量（放射免疫测定法）评估疾病活动度。与先前的研究一致，我们发现肌酐清除率升高。然而，该变量与尿生长激素排泄之间未发现相关性。尿白蛋白和β2-微球蛋白排泄率与我们之前对27名成年对照受试者的结果相比无显著差异。尿生长激素排泄与尿白蛋白或β2-微球蛋白排泄率之间无相关性。溴隐亭治疗使尿生长激素排泄量从220降至91纳克/24小时，p<0.01，但上述肾功能变量未出现显著改变。
